 SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced preclinical findings of ALLO-316, an AlloCAR TTM therapy targeting CD70, in models of acute myeloid leukemia AML. Data were presented in a poster session today at the 62nd Annual Meeting of the American Society of Hematology. 